• Skip to primary navigation
  • Skip to main content
  • Skip to primary navigation
  • Skip to main content
Choose which site to search.
University of Arkansas for Medical Sciences Logo University of Arkansas for Medical Sciences
Winthrop P. Rockefeller Cancer Institute: UAMS Myeloma Center
  • UAMS Health
  • Jobs
  • Giving
  • About
    • Our Collaborations
    • Our History
    • Why Choose Us?
    • Calendar of Events
  • Patient Care
  • Research
  • Resources
    • Myeloma Magazine
    • Video Library
  • Contact
  1. University of Arkansas for Medical Sciences
  2. Winthrop P. Rockefeller Cancer Institute
  3. UAMS Myeloma Center
  4. Publications

Publications

Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma

Blood Advances, American Society of Hematology

November 2021

Primary author: Mauricio Zangari, M.D. 

The minimal residual disease (MRD) test can identify myeloma in the bone marrow of patients in remission by standard criteria. This research describes 568 patients who achieved MRD negativity after autologous stem cell transplant. With a follow-up of nearly 10 years, 61% of patients remained MRD negative after stem cell transplant, while 39% became MRD positive at six years, with the highest risk of MRD conversion five years after treatment. MRD conversion was linked to increased risk of relapse. Importantly, not all MRD positive patients experienced a relapse, and 27% of positive patients had not relapsed at 10 years. MRD conversion from negative to positive correctly predicted relapse in 70% of patients. This study demonstrates the benefits of continued MRD assessment.

TRIP13 modulates protein de-ubiquitination and accelerates tumor development and progression of B cell malignancies

The Journal of Clinical Investigation

June 1, 2021

Primary author: Can Li, Ph.D.

The carefully orchestrated abundance of proteins within a cell controls cell proliferation. Proteasome inhibitors act as anti-myeloma agents by disabling the machine that degrades cellular proteins tagged with a molecule called ubiquitin. The increased ubiquinated protein levels within the tumor cell causes stress-induced cell death. The removal of the ubiquitin “tag” from cellular proteins, a process termed “deubiquitination,” can also increase protein stability. Research at UAMS identified TRIP13 as a gene abnormally overexpressed in high-risk myeloma. The research also noted that TRIP13 causes resistance to proteasome inhibitors, and that the tumor promoting activity of TRIP13 can be overcome by inhibiting deubiquitinase, called USP7. The data point to the central importance of protein stability in cancer biology and that targeting ubiquitination of proteins may complement the already established anti-myeloma effects of proteasome inhibition therapy. 

Posted by Chadley Uekman on May 5, 2022

Filed Under: Winter/Spring 2022

Winthrop P. Rockefeller Cancer Institute LogoWinthrop P. Rockefeller Cancer InstituteWinthrop P. Rockefeller Cancer Institute
Address: 449 Jack Stephens Dr., Little Rock, AR 72205
Parking Deck: 4018 W Capitol Ave., Little Rock, AR 72205
New Appointments: (501) 686-7105
Information Line: (501) 804-3557
  • Facebook
  • Twitter
  • Instagram
  • YouTube
  • LinkedIn
  • Pinterest
  • Disclaimer
  • Terms of Use
  • Privacy

© 2023 University of Arkansas for Medical Sciences